Accessibility Menu
Pliant Therapeutics logo

Pliant Therapeutics

(NASDAQ) PLRX

Current Price$1.16
Market Cap$68.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-95%
5 Year-96%
1 Year-17%
1 Month-7%
Pliant Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.112026-07-16
Pliant Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.77%USD 1.132026-07-09
1 month-6.72%USD 1.192026-06-16
3 month-16.54%USD 1.332026-04-17
Year to date-9.02%USD 1.222025-12-31
1 year-17.16%USD 1.342025-07-16
3 year-93.78%USD 17.842023-07-17
5 year-95.52%USD 24.792021-07-16
Since inception-94.79%USD 21.302020-06-03

Pliant Therapeutics Financials at a Glance

Market Cap

$68.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$113.22M

EPS (TTM)

-$1.84

P/E Ratio

-0.60

Dividend

$0.00

Beta (Volatility)

1.17 (Average)

Price

$1.16

Volume

405,604.808

Open

$1.09

Previous Close

$1.15

Daily Range

$1.09 - $1.16

52-Week Range

$1.08 - $1.95

Estimated Earnings Date

Aug 6, 2026

PLRX News

Physician going over results with patient (1)

Why Shares of Pliant Therapeutics Are Rising Tuesday

James HalleySep 26, 2023
Scientists in a lab

Why Pliant Therapeutics Stock Is Skyrocketing This Week

Keith SpeightsJan 26, 2023
cash

Could Pliant Therapeutics Stock Double Your Money?

George Budwell, PhDJul 18, 2022
piggybank rocket

Why Pliant Therapeutics Stock Is Crushing It Today

George Budwell, PhDJul 11, 2022
Cheering-crowd-of-healthcare-providers-getty

Why Pliant Therapeutics Stock Is Surging Today

Cory RenauerSep 7, 2021
IPO and stock chart

Could This Recent IPO Biotech Become the Next Moderna?

Keith SpeightsJun 13, 2020
IPO (2)

Pliant Therapeutics Up 33% on IPO Pricing

Brian Orelli, PhDJun 3, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pliant Therapeutics

Pliant Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for fibrotic diseases, which are characterized by tissue scarring and organ dysfunction. The company leverages a proprietary platform to target integrins, proteins that play a crucial role in disease progression. This innovative approach seeks to address underlying causes rather than just managing symptoms.

Products and Services

Therapies for idiopathic pulmonary fibrosis (IPF), a disease with limited treatment options.

Therapies for primary sclerosing cholangitis (PSC), aimed at a disease with high unmet medical needs.

What Makes Pliant Therapeutics, Inc. Special

Pliant Therapeutics, Inc. is distinct for its integrin-targeting strategy, which addresses the root causes of fibrotic diseases. The company's innovative platform offers a significant competitive advantage in a landscape where existing treatments often fail to tackle the underlying pathology. By focusing on unmet medical needs, Pliant aims to improve patient outcomes significantly.

Five Things You Need to Know

Pliant’s therapies target fibrotic diseases, where tissue scarring leads to organ dysfunction.

The company utilizes a proprietary platform to specifically target integrins, impacting disease progression.

Leadership includes experts in drug development and commercialization, positioning it well for market entry.

Strategic partnerships and collaborations enhance research capabilities and clinical progress.

Pliant focuses on markets with high unmet needs, like IPF and PSC, indicating potential for significant market impact.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

49

CEO

Bernard Coulie, MD, PhD

Website

www.pliantrx.com

Headquarters

South San Francisco, CA 94080, US

PLRX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-59.06%

Return on Capital

-71.36%

Return on Assets

-55.88%

Earnings Yield

-1.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$68.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

61.92M

Volume

405.60K

Avg. Volume

554.41K

Financials (TTM)

Gross Profit

-$711.00K

Operating Income

-$119.21M

EBITDA

-$107.98M

Operating Cash Flow

-$98.70M

Capital Expenditure

-$112.00K

Free Cash Flow

-$98.81M

Cash & ST Invst.

$170.89M

Total Debt

$28.78M

Pliant Therapeutics Performance Analysis

Pliant Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 9,685,00027.9%
20232023-12-31USD 1,580,000-83.7%
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Pliant Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Pliant Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.948.2%
20232023-12-31USD -2.75-6.4%
20242024-12-31USD -3.4726.4%
20252025-12-31USD -2.43-29.9%
Pliant Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3022.8%
Q32025-09-3039.4%
Q42025-12-3111.6%
Q12026-03-3115.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$264.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$68.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.40M

N/A

Employees

49

N/A

Net Income

-$20.04M

+64.3%

EBITDA

-$19.78M

+64.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$170.89M

-44.1%

Total Debt

$28.78M

-52.2%

Accounts Receivable

$914.00K

-45.7%

Inventory

$0.00

N/A

Long Term Debt

$27.07M

-54.4%

Short Term Debt

$1.71M

+122.2%

Return on Assets

-55.88%

N/A

Return on Invested Capital

-62.01%

N/A

Free Cash Flow

-$19.23M

+60.9%

Operating Cash Flow

-$19.23M

+60.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CLNNClene Inc.
$5.92+4.04%
GUTSFractyl Health, Inc.
$0.81-5.19%
COYACoya Therapeutics, Inc.
$4.54-1.30%
ADVMAdverum Biotechnologies, Inc.
$4.36+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
PATHUiPath
$12.15+0.01%
JOBYJoby Aviation
$7.23-0.01%

Questions About PLRX

What is the current price of Pliant Therapeutics?

Pliant Therapeutics is trading at $1.15 per share.

What is the 52-week range for Pliant Therapeutics?

Over the past 52 weeks, Pliant Therapeutics has traded between $1.08 and $1.95.

How much debt does Pliant Therapeutics have?

As of the most recent reporting period, Pliant Therapeutics reported total debt of $28.78M.

How much cash does Pliant Therapeutics have on hand?

Pliant Therapeutics reported $22.19M in cash and cash equivalents in its most recent financial results.

What is Pliant Therapeutics’s dividend yield?

Pliant Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services